Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of ABP2111Na tablets in overweight or obese adults
ChiCTR2500098510Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABP2111Na in obesity and Overweight (3 arms), sponsored by Peking University People's Hospital. Primary endpoints: Percentage change in body weight from baseline and Proportion of participants with at least 5% weight loss from baseline. Started Mar 2025; status: recruiting.
02
Drugs
ABP2111Na
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR2500098510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098510.